Joyzyme Group Limited Overview
Joyzyme Group is a micro-cap Shenzhen-based medical device and health products company listed on Hong Kong's GEM board. Its legacy and still-dominant franchise is the research, manufacture and sale of in-vitro diagnostic (IVD) reagents for male infertility — a niche in which it holds a portfolio of 32 registered male fertility reagents — supplemented by parasite and Epstein-Barr virus antibody tests and auxiliary reproductive supplies. Revenue has been essentially flat at RMB24–28 million for eight years while losses have persisted every year since at least 2020. Following a change of control in October 2025 to enzyme-technology entrepreneur Dr. Zhou Xunyong, the group is repositioning toward women's health (via the June 2025 Keyue acquisition), Canadian-licensed nutraceuticals (Nutronic brand) and "silver economy" longevity products, under a new name evoking enzyme-based wellness. The investment case is now one of transition: a cash-rich, debt-light but shrinking-demand diagnostics business funding an unproven consumer health pivot.
Company's own description (AR2025 / IR2026)
In its notes to the financial statements, the group describes itself as principally engaged in the research and development, manufacturing, marketing and sale of (i) biological reagents and auxiliary reproductive supplies and equipment and (ii) healthcare products and supplements in the PRC. The AR2025 management discussion frames the biological reagents business as continued focus on male fertility IVD reagents, while the healthcare segment is presented as the vehicle for women's health, longevity and nutraceutical expansion. The co-chairman's statement in AR2025 positions the group's mission around the slogan "Fighting for fertility, building better beginnings" and describes a pivot from product supply toward an integrated healthcare service ecosystem.
Independent characterisation
Joyzyme is, in economic substance, two very different businesses held inside a cash shell:
-
A mature, high-gross-margin specialty IVD reagent maker (≈78% of H1 2026 revenue) selling semen/seminal plasma biochemical and related reagents to PRC hospital andrology departments, reproductive medicine centres and distributors. Gross margins on this business are high (group margin was 67–68% before the healthcare segment diluted it), but scale is tiny (≈RMB25.5M p.a.) and the end-market is structurally pressured by China's collapsing birth rate (5.63‰ in 2025 versus 6.77‰ in 2024, cited in AR2025 from the National Bureau of Statistics).
-
An early-stage consumer health business (≈22% of H1 2026 revenue) comprising Hunan Keyue Biotechnology (women's health supplements with a caregiver-service model, brands Yukunshu and Qinghuiyue) and the relaunched Canadian Nutronic brand (27 Health Canada Natural Health Product licences). This segment is loss-making at the segment-result level (−RMB0.99M in H1 2026) and carries a lower gross margin (≈45% in FY2025).
The group holds ≈RMB39M of cash and deposits against equity of ≈RMB49M (June 2026), so cash constitutes roughly 80% of book value; the operating businesses are being funded from this balance while new related-party and money-lender debt has been introduced.
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model mix | ~100% product sales (reagents, consumables, equipment, supplements). No subscription, licensing or recurring service revenue disclosed. Keyue's planned "caregiver service and experience" model is aspirational; no service revenue line is reported |
| Value chain position | Upstream manufacturer (reagents produced in Shenzhen); healthcare products appear to be a mix of own-brand and sourced/contract-manufactured goods (manufacturing arrangements not disclosed) |
| Customer types | Hospitals, reproductive/andrology clinics and distributors for IVD (per prospectus framing and segment description); wholesale and e-commerce channels for healthcare products. One healthcare customer ("Customer A") contributed RMB2.27M (13.7% of group revenue) in H1 2026 |
| Credit terms | 30–180 days for certain long-term customers; deposits required from others (IR2026 note 14) |
| End-markets | PRC male infertility diagnostics; PRC infectious disease serology (liver fluke/parasite, EBV); PRC assisted reproduction consumables; PRC women's health supplements; Canadian/North American natural health products (early) |
| Geography | 100% of revenue from the PRC (FY2025, H1 2026) |
Strategy
Stated strategic themes (AR2025, IR2026)
Management's stated strategy can be summarised in five themes, paraphrased from the AR2025 co-chairman's statement and MD&A and the IR2026 outlook:
-
Pivot from product supply to an integrated healthcare service ecosystem, explicitly framed around the "silver economy" and personalised healthcare.
-
Women's health platform via Keyue, converting it into a "full-spectrum" service provider combining functional supplements, caregiver services and customer experience, expanded through offline business collaborations; flagship brands Yukunshu and Qinghuiyue. AR2025 targets "substantial growth in revenue in 2026".
-
Nutronic brand strategy, using the East Asian "nominal age" (虛歲) concept to position preconception and pregnancy nutrition, leveraging 27 Health Canada licences.
-
"Dual-engine" R&D across Canada and the PRC, pairing North American scientific credibility with PRC supply-chain efficiency, and expanding e-commerce and wholesale channels across North America, Southeast Asia and China to reduce single-market dependence.
-
Sustain the legacy diagnostics technology base, especially chemiluminescence applications (sperm mitochondrial reagent, AMH).
Strategic initiatives (last 24 months)
| Date | Initiative | Type | Status |
|---|---|---|---|
| Jul 2024 | Enzyme-based product trading via online platform and B2B | New business | Announced; separate results not reported |
| Aug–Oct 2024 | Appointment of enzyme and molecular pharmacology scientists as NEDs | Governance / capability | Bu Su remains; Xu Ming resigned Mar 2026 |
| Apr–Jun 2025 | Keyue acquisition (91%) | Diversification M&A | Completed; RMB3.6M revenue H1 2026 |
| Oct–Dec 2025 | Change of control to Dr. Zhou Xunyong | Ownership | Completed; 50.35% |
| Late 2025 | Three Class I chemiluminescence ancillary reagent registrations | Product | Registered |
| Jan–Feb 2026 | Rebrand to Joyzyme Group Limited | Corporate identity | Completed |
| Early 2026 | Nutronic relaunch | New brand | ≈RMB115k revenue H1 2026 |
| H1 2026 | Sperm Morphology Analysis Assay Kit — Class II registration | Product | H2 2026 launch planned |
| H1 2026 | Seminal plasma biochemical QC clinical research | R&D | Ongoing |
ESG commitments
AR2025 references a commitment to "better births" advocacy, women's empowerment, reduced parenting stress and ethical governance across PRC, Hong Kong and Canadian operations. No quantified ESG targets were identified.
Cost programmes
None announced.
Medium-term financial targets / guidance
No quantified medium-term targets or formal guidance have been published. The only forward-looking financial statement is the qualitative aim of substantial revenue growth in 2026 from the Keyue platform.
Products & Services
Product-level disclosure in periodic reports is aggregated by category; individual SKU names, specifications and prices are not published in the retrieved filings. The catalogue below goes as granular as the public record allows.
Biological Reagents & Auxiliary Reproductive Supplies segment
| Product line | Description | Key details | Target customer | Year / status | Pricing |
|---|---|---|---|---|---|
| Male fertility IVD reagents (32 products) | Reagents for assessing semen and seminal plasma parameters in male infertility workups | Core franchise; RMB19.4M FY2025 (76.2% of segment); RMB10.4M H1 2026 (+4.4% YoY; 79.8% of segment). Count rose from 31 (end-2025) to 32 (mid-2026) | Hospital andrology departments, reproductive medicine centres, distributors | Ongoing | — |
| Sperm Morphology Analysis Assay Kit (improved) | Kit for morphological assessment of sperm | Class II medical device registration completed H1 2026; launch planned H2 2026 | As above | 2,026 | — |
| Chemiluminescence ancillary reagents (3 products) | Ancillary reagents for chemiluminescence-based male fertility assessment | Registered as Class I medical devices in late 2025 | As above | 2,025 | — |
| Sperm mitochondrial diagnostic reagent (pipeline) | Chemiluminescence application for sperm mitochondrial function | Development; referenced in AR2025 and IR2026 outlook | As above | Pipeline | — |
| Anti-Müllerian hormone (AMH) assay (pipeline/application) | Chemiluminescence application of AMH for reproductive potential assessment | Development; referenced in outlook | Fertility clinics | Pipeline | — |
| Seminal plasma biochemical QC (research) | Clinical research for quality control of seminal plasma biochemical products | Drove +24.4% R&D spend in H1 2026 | Internal / regulatory | 2,026 | — |
| Parasite antibody detection reagents (2 products) | Serological detection of parasite antibodies; includes liver fluke (Clonorchis) IVD reagent | RMB3.9M FY2025; RMB1.40M H1 2026 (−3.9% YoY) | Hospitals, CDC/infectious disease labs (endemic regions) | Ongoing; liver fluke sales ≈RMB2.4M in FY2018 | — |
| Epstein-Barr virus antibody detection reagent (1 product) | EBV serology (relevant to nasopharyngeal carcinoma screening in South China) | ≈RMB0.6M FY2025 (derived residual); RMB0.18M H1 2026 (−22.5% YoY) | Hospitals, screening programmes | Ongoing | — |
| Auxiliary reproductive supplies and equipment | Consumables and equipment for reproductive medicine | RMB1.6M FY2025; RMB1.04M H1 2026 (+47.0% YoY) | Reproductive centres | Ongoing | — |
Healthcare Products & Supplements segment
| Product line / brand | Description | Key details | Target customer | Year / status | Pricing |
|---|---|---|---|---|---|
| Keyue — Yukunshu (玉坤舒) | Flagship women's health brand | Positioned for physiological and recovery needs across female life cycle | Female consumers, PRC | Acquired Jun 2025 | — |
| Keyue — Qinghuiyue (清徽悅) | Flagship women's health brand | As above | Female consumers, PRC | Acquired Jun 2025 | — |
| Keyue caregiver service model | "Medical supplement product, caregivers' service and experience" model, expanded via business cooperation | Aspirational; no separate service revenue reported | Female consumers | 2025–26 | — |
| Nutronic | Canadian natural health products brand; preconception/fertility nutrition messaging ("Loving you starting from a sperm") and longevity products | 27 valid Health Canada Natural Health Product licences; revenue ≈RMB115,000 in H1 2026 | Couples preparing for conception; ageing consumers | Relaunched early 2026 | — |
| Longevity / "silver economy" functional foods | Anti-ageing and energy-support supplements for elderly and parents | Stated development direction; no named products | Elderly consumers, parents | Pipeline | — |
| Enzyme-based products (trading) | Online/B2B trading of enzyme-based products announced Jul 2024 | Not reported as a separate revenue line; current status not disclosed | Consumers/B2B | Announced 2024 | — |
Product revenue detail (half-year, IR2026 note 4)
| Product revenue (CNY K) | H1 2025 | H1 2026 |
|---|---|---|
| Male fertility IVD reagents | 9,933 | 10,371 |
| Parasite antibody detection reagents | 1,460 | 1,403 |
| EBV antibody detection reagents | 231 | 179 |
| Auxiliary reproductive supplies and equipment | 705 | 1,036 |
| Healthcare products and supplements | 0 | 3,568 |
| Total | 12,329 | 16,557 |
Financial Narrative
Income statement
FY2021–23 EPS derived from net income ÷ weighted shares. FY2025 operating income derived (17.77 − 8.4 − 13.1 − 3.2 ≈ −6.93; excludes RMB1.2M trade receivable impairment). Dividends: no dividend recommended for FY2024 or FY2025 (AR2025); no dividend was identified for FY2021–FY2023.
Margins and growth
Revenue CAGR FY2021–FY2025: ≈2.0% (derived: 28.28 / 26.13 over four years). Excluding the acquired Keyue contribution, organic revenue CAGR is approximately −0.6%.
Cash flow
No buybacks occurred in H1 2026 (IR2026: no purchase, sale or redemption of listed securities).
Ratios
ROE FY2024 uses year-end equity; FY2025 uses average equity; H1 2026 annualises H1 loss on average equity. DSO = net trade receivables ÷ revenue × 365 (H1 annualised). Inventory and payable days, and therefore the full cash conversion cycle, are not computable with the data retrieved for prior years.
Commentary on trends, inflections and drivers
Revenue: eight years of stagnation, broken only by acquisition. Group revenue has oscillated in a RMB22–29M band since 2016 (aggregator history: FY2016 ≈25.4M, FY2018 ≈28.7M peak, FY2020 ≈22.0M COVID trough). The legacy reagent franchise grew just 0.7% in FY2025 and 5.4% in H1 2026. All of FY2025's 11.5% growth and most of H1 2026's 34.3% growth came from consolidating Keyue. On a like-for-like basis, the core business is flat in a market where births are falling sharply, which suggests share gains or price/mix offsets that management does not quantify.
Gross margin: high but now diluting. The reagent business sustains gross margins in the high 60s; group gross margin fell 4.5 points to 62.8% in FY2025 and to 63.8% in H1 2026 (from 68.3%) purely on mix, as healthcare products run at ≈45%. Further growth of the healthcare segment will mechanically compress group gross margin.
Operating costs: structurally too high for the revenue base. Operating expenses (selling, admin, R&D) of RMB24.7M in FY2025 exceed gross profit by ≈RMB7M. Administrative expense jumped 21.5% in FY2025 on professional fees for the Keyue acquisition and the mandatory general offer plus Keyue's own overheads. Selling expenses (≈30% of revenue) are high, consistent with a distributor- and hospital-detailing model. The group has not been profitable at the operating level in any year in the review period.
Below-the-line volatility. FY2025's reported loss was cushioned by a one-off ≈RMB2.6M gain from writing off an amount due to an associate (other income +374%) and a RMB0.22M impairment reversal; stripping these out, the underlying FY2025 loss was closer to RMB7.8M, the worst since FY2020. Trade receivable impairments rose more than twelve-fold to RMB1.2M in FY2025, which management attributes to weaker customer repayment capacity in the PRC.
Balance sheet: cash-rich but quality of receivables is a concern. Cash and deposits of RMB39–42M cover the market's entire non-cash book value several times over. However, the RMB6.1–6.3M credit loss allowance represents over a third of gross receivables, and more than a quarter of net receivables are aged over 181 days (RMB3.5M at June 2026). The group has introduced external debt for the first time — a HK$4M money-lender loan at 9% (FY2025, since extended 12 months) and HK$5M of 3% loans from the controlling shareholder (H1 2026) — despite holding ample cash, presumably reflecting the location of cash (largely in the PRC operating subsidiary) versus Hong Kong-level funding needs. Finance costs rose more than threefold in H1 2026.
Cash burn is accelerating. Operating cash outflow tripled to RMB4.8M in H1 2026. At this run-rate (≈RMB10M p.a. including capex), the cash pile provides roughly four years of runway absent a turnaround or new equity.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key products/brands |
|---|---|---|
Biological reagents and auxiliary reproductive supplies and equipment | Male fertility IVD reagents; parasite antibody detection reagents; EBV antibody detection reagent; auxiliary reproductive supplies and equipment | 32 male fertility IVD reagents (mid-2026); Sperm Morphology Analysis Assay Kit (Class II); chemiluminescence ancillary reagents (Class I) |
Healthcare products and supplements | Women's health supplements (Keyue); Canadian natural health products (Nutronic); enzyme-based products (status of 2024 trading initiative not separately reported) | Yukunshu (玉坤舒), Qinghuiyue (清徽悅), Nutronic |
Segment revenue (CNY Mn)
| Segment revenue (CNY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Biological reagents & auxiliary reproductive supplies | — | 25.4 | 25.5 |
Healthcare products & supplements | — | 0 | 2.8 |
Total group revenue | 24.63 | 25.36 | 28.28 |
Segment Metrics FY2025 Details
| Segment metrics FY2025 (AR2025) | Value |
|---|---|
Biological reagents segment YoY growth | +0.7% (+RMB173,000) |
Healthcare segment revenue contribution | ≈9.9% of group revenue (derived) |
Healthcare segment gross margin | ≈45.0% |
Group gross margin | 62.8% (FY2024: 67.3%) |
Revenue by Segment and Segment Margins & Growth (%)
| Segment (CNY K) | H1 2025 | H1 2026 |
|---|---|---|
Biological reagents — revenue | 12,329 | 12,989 |
Biological reagents — segment result | 588 | 1,567 |
Healthcare products — revenue | 0 | 3,568 |
Healthcare products — segment result | -545 | -993 |
Unallocated administrative expenses | -2,345 | -2,617 |
Loss before tax | -2,369 | -2,428 |
Derived H1 metrics | H1 2025 | H1 2026 |
Biological reagents segment margin (%) | 4.8 | 12.1 |
Healthcare segment margin (%) | — | -27.8 |
Biological reagents share of revenue (%) | 100.0 | 78.4 |
Healthcare share of revenue (%) | 0.0 | 21.6 |
Group Entities
| Entity | Role | Ownership |
|---|---|---|
Joyzyme Group Limited (Cayman) | Listed holding company | Anselme 50.35%; public float ≈49.65% |
BVI intermediate holding companies | — | 100% |
Shenzhen Huakang Bio-Medical Engineering Limited | Core IVD manufacturer; HNTE status | 100% (indirect) |
Hunan Keyue Biotechnology Company Limited | Women's health products | 91% (indirect); 9% held directly by ED Zhang Yujing |
Canadian operating entity (Nutronic) | Natural health products; holds Health Canada licences | Entity name and ownership not disclosed in retrieved filings |
Associate (19% stake acquired 2023) | Anoectochilus extract IP | Carrying value nil at June 2026; amount due to associate written off in FY2025 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 26.13 | 25.33 | 24.63 | 25.36 | 28.28 |
Revenue growth YoY (%) | 18.9 | -3.1 | -2.8 | 3.0 | 11.5 |
Gross profit (CNY Mn) | 16.46 | 16.91 | 16.09 | 17.07 | 17.77 |
Selling & distribution expenses (CNY Mn) | — | — | — | 8.5 | 8.4 |
Administrative expenses (CNY Mn) | — | — | — | 10.8 | 13.1 |
R&D expenses (CNY Mn) | — | — | — | 2.8 | 3.2 |
Operating income (CNY Mn) | -4.58 | -5.09 | -7.39 | -5.01 | -6.93 |
EBITDA (CNY Mn) | -0.85 | 0.19 | -2.55 | -3.41 | — |
Other income (CNY Mn) | — | — | — | 0.70 | 3.31 |
Pre-tax income (CNY Mn) | -3.90 | -3.01 | -5.78 | -4.16 | — |
Net income attributable (CNY Mn) | -4.22 | -3.08 | -5.78 | -4.16 | -5.01 |
Weighted avg shares (M) | 400.00 | 404.64 | 415.97 | 482.48 | — |
Basic EPS (MYR Bn cents) | -1.06 | -0.76 | -1.39 | -0.86 | -1.00 |
Diluted EPS (MYR Bn cents) | -1.06 | -0.76 | -1.39 | -0.86 | -1.00 |
Dividend per share (MYR Bn) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 63.0 | 66.8 | 65.3 | 67.3 | 62.8 |
Operating margin (%) | -17.5 | -20.1 | -30.0 | -19.8 | -24.5 |
EBITDA margin (%) | -3.3 | 0.7 | -10.4 | -13.4 | — |
Net margin (%) | -16.2 | -12.2 | -23.5 | -16.4 | -17.7 |
R&D % of revenue | — | — | — | 11.0 | 11.3 |
Income Statement and Per-Share Data
| Metric (CNY K) | H1 2025 | H1 2026 |
|---|---|---|
Revenue | 12,329 | 16,557 |
Cost of sales | -3,913 | -5,993 |
Gross profit | 8,416 | 10,564 |
Other income | 231 | 121 |
Other losses (FX) | -147 | -289 |
Selling & distribution | -3,520 | -4,067 |
Administrative | -5,174 | -5,975 |
R&D | -1,839 | -2,288 |
Trade receivable impairment, net | -381 | -250 |
Reversal of loan/consideration impairment | 113 | 0 |
Finance costs | -68 | -244 |
Loss before tax | -2,369 | -2,428 |
Loss attributable to owners | -2,369 | -2,347 |
Basic & diluted LPS (MYR Bn cents) | -0.47 | -0.47 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (CNY Mn) | — | — | — | 66.61 |
Cash, bank balances & >3-month deposits (CNY Mn) | — | — | 36.50 | 41.94 |
Short-term borrowings (CNY Mn) | — | — | 0 | 3.60 |
Lease liabilities — current (CNY Mn) | — | — | — | 0.65 |
Lease liabilities — non-current (CNY Mn) | — | — | — | 0.70 |
Total debt incl. leases (CNY Mn) | — | — | 1.20 | 4.96 |
Net debt (negative = net cash) (CNY Mn) | — | — | -35.30 | -36.98 |
Total equity (CNY Mn) | — | — | 54.05 | 51.16 |
Goodwill (CNY Mn) | — | — | — | 0 |
Intangible assets (CNY Mn) | — | — | — | 0.78 |
Net current assets / working capital (CNY Mn) | — | — | — | 42.51 |
Gearing — debt incl. leases / equity (%) | — | — | 2.2 | 9.7 |
Balance sheet snapshot (CNY K) | 31 Dec 2025 | 30 Jun 2026 | — | — |
Property, plant & equipment | 7,223 | 6,722 | — | — |
Right-of-use assets | 1,343 | 2,272 | — | — |
Intangible assets (capitalised development costs) | 781 | 509 | — | — |
Inventories | 3,241 | 3,631 | — | — |
Trade & bills receivables (net) | 9,807 | 11,932 | — | — |
Gross trade & bills receivables | 15,926 | 18,212 | — | — |
Credit loss allowance | 6,119 | 6,280 | — | — |
Bank deposit > 3 months | 5,000 | 5,000 | — | — |
Bank balances and cash | 36,940 | 34,242 | — | — |
Total current assets | 57,262 | 56,719 | — | — |
Total assets | 66,609 | 66,222 | — | — |
Interest-bearing borrowings (money lender, 9%) | 3,604 | 3,604 | — | — |
Borrowing from controlling shareholder (3%) | 0 | 1,754 | — | — |
Lease liabilities (total) | 1,353 | 2,305 | — | — |
Total current liabilities | 14,754 | 16,365 | — | — |
Net current assets | 42,508 | 40,354 | — | — |
Total equity | 51,156 | 49,127 | — | — |
Accumulated losses | -17,779 | -20,126 | — | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Analysis
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid (CNY Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (CNY Mn) | 0 | 0 | 0 | 0 | 0 |
Cash flow (CNY K) | H1 2025 | H1 2026 | — | — | — |
Net cash used in operating activities | -1,480 | -4,795 | — | — | — |
Net cash from/(used in) investing activities | 4,785 | -198 | — | — | — |
Net cash from financing activities | 1,575 | 1,996 | — | — | — |
PP&E purchases (capex) | 404 | 298 | — | — | — |
Free cash flow (derived: OCF − capex) | -1,884 | -5,093 | — | — | — |
Cash & equivalents, end of period | 36,725 | 34,242 | — | — | — |
Margin Analysis (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 | H1 2026 (annualised where relevant) |
|---|---|---|---|
ROE (%) | -7.7 | -9.5 | -9.7 |
ROA (%) | — | -7.5 | -7.3 |
ROIC (%) | — | n/m (negative operating profit) | n/m |
Current ratio (x) | — | 3.88 | 3.47 |
Debt incl. leases / equity (%) | 2.2 | 9.7 | 15.6 |
Net debt / EBITDA (x) | n/m (net cash, negative EBITDA) | n/m | n/m |
Interest coverage (x) | n/m | n/m (operating loss) | n/m |
Asset turnover (x) | — | 0.42 | 0.50 |
DSO on net receivables (days) | — | 127 | 131 |
Credit loss allowance / gross receivables (%) | — | 38.4 | 34.5 |
Region revenue (CNY Mn)
| Region revenue (CNY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
PRC | 24.63 | 25.36 | 28.28 |
Hong Kong | 0 | 0 | 0 |
Canada / North America | 0 | 0 | 0 |
Other | 0 | 0 | 0 |
Region revenue (CNY K) | H1 2025 | H1 2026 | — |
PRC | 12,329 | 16,557 | — |
Share Price History
| Date | Price reference | Context |
|---|---|---|
9 Apr 2020 | 0.125 | Market price on option grant date |
9 Oct 2025 | 0.126 | Price paid by Anselme in private SPA |
5 Dec 2025 | 0.395 | Market price on option exercise date |
9 Dec 2025 | 0.405 | Market price on option exercise date |
Recent (Oct 2026, timestamp unconfirmed) | 0.380 | ET Net real-time quote retrieved during research |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation (HKD Mn) | 196 | 515.472M shares × HK$0.38 |
P/E | n/m | Loss-making |
P/B (x) | 3.7 | Equity RMB49.1M ≈ HK$53.6M (assumed HK$1.09/RMB) |
EV (HKD Mn) | 159 | Market cap less net cash ≈ RMB33.8M (≈HK$36.8M) at 30 Jun 2026 |
EV/Sales TTM (x) | 4.5 | TTM revenue RMB32.5M (FY2025 − H1 2025 + H1 2026) ≈ HK$35.4M |
EV/EBITDA | n/m | Negative EBITDA |
Capital Markets
| Item | Status |
|---|---|
Analyst coverage / consensus | None identified |
Dividend history | No dividends declared in any period covered by this research; policy: discretionary based on results, capital needs and cash flow (AR2025) |
Dividend policy | No fixed payout policy |
Buyback authorisations | Standard general mandate customary for HK issuers; no repurchases executed in H1 2026 |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | HK$4M money-lender loans (9%, maturity extended 12 months from original); HK$5M controlling-shareholder loans (3%, on demand); lease liabilities RMB1.6M current, RMB0.7M non-current (30 Jun 2026). No bank facilities |
Equity issuance history | 400M shares (2020–21) → 414.47M (Apr 2023) → 418.47M (Aug 2023) → 438.47M (Jan 2024 placing) → 500.47M (Apr 2024) → 515.47M (Dec 2025 option exercises) |
Shares in issue (M, year end) | FY2021 |
Ordinary shares in issue | 400.00 |
Analyst Conclusions
Management guidance
Management offers only qualitative guidance: cautious optimism amid soft PRC consumer demand and modest GDP growth; scale-up of healthcare products and supplements; overseas expansion (North America, Southeast Asia); e-commerce and wholesale diversification; continued chemiluminescence development; launch of the sperm morphology kit in H2 2026; and an aspiration for substantial revenue growth in 2026 from Keyue.
Consensus
No sell-side coverage or consensus estimates exist.
Bull case
-
Legacy business has hidden earnings power. The reagent segment result nearly tripled to RMB1.57M in H1 2026 on 5% growth; if head-office costs normalise after one-off 2025 deal and offer fees, the group could approach break-even on an expanded revenue base.
-
Cash cushion limits downside. ≈RMB39M cash and deposits against minimal external debt gives several years of runway and optionality for bolt-on deals.
-
New controller brings capital and a thesis. Dr. Zhou's enzyme IP, consumer health network and willingness to fund at 3% could transform Joyzyme into a platform for his health businesses, with Keyue already annualising above RMB7M revenue.
Bear case
-
No evidence of a profitable model. Losses in every year since at least 2020; underlying FY2025 loss (≈RMB7.8M ex one-offs) was the worst since the pandemic year, and operating cash burn tripled in H1 2026.
-
Valuation detached from fundamentals. At ≈3.7x book and ≈4.5x EV/sales for a shrinking-market, loss-making micro-cap, the shares trade at roughly 3x the price the controller paid in October 2025.
-
Governance and related-party complexity. Co-chair owns 9% of Keyue; the controller lends to the company; the board lost six directors in 15 months; disclosure inconsistencies appear in the latest interim report.
Key catalysts and monitorables (next 12 months)
| Monitorable | Why it matters | Timing |
|---|---|---|
| HNTE certificate renewal for Shenzhen Huakang | Preserves 15% tax rate and signals R&D credentials | Expiry 14 Nov 2026 |
| Sperm morphology kit commercial launch | Test of new-product traction in core segment | H2 2026 |
| FY2026 annual results | Whether Keyue/Nutronic deliver "substantial" growth and whether losses narrow | ~Mar 2027 |
| Operating cash flow trend | Runway and potential need for equity raise | FY2026 results |
| Receivables ageing and impairments | Customer credit stress | Semi-annual |
| Any asset injections or transactions with controller's other companies | Potential transformation and connected-transaction scrutiny | Unscheduled |
| Equity fundraising | Dilution risk given GEM history | Unscheduled |
| Board appointments (replacing Xu Ming) | Governance stability | Unscheduled |
| Money-lender loan maturity / refinancing | Liquidity at HK level | Extended 12 months from original drawdown |
Analyst verdict
Joyzyme Group is best understood not as a growing fertility-health company but as a small, cash-rich specialty diagnostics business in the early stages of a controller-driven transformation whose economics are unproven. The legacy male fertility reagent franchise is genuinely interesting: it carries high-60s gross margins, a broad registered portfolio, recent regulatory wins (Class I chemiluminescence reagents, a Class II sperm morphology kit), and showed clear operating leverage in H1 2026. Yet it has not grown organically in years, its end-market is shrinking as China's births fall, and its customers are paying more slowly — over a third of gross receivables are provisioned.
The diversification strategy layers a lower-margin, marketing-intensive consumer health business on top. Keyue was acquired for a token sum and is producing revenue, but the healthcare segment lost nearly RMB1M in the first half of 2026, and Nutronic's contribution is immaterial. Group-level cash burn tripled even as revenue rose by a third, and the company has begun borrowing at the holding level despite carrying ample PRC cash.
The October 2025 change of control is the pivotal event. Dr. Zhou acquired control at roughly HK$0.126 per share; the market now values the stock near HK$0.38, implying investors are paying for a transformation premium — presumably expectations of enzyme-based product synergies or future asset injections — for which no concrete plan, target or transaction has been disclosed. Governance signals are mixed: committees are properly constituted and the chair/CEO roles are separated, but related-party arrangements, rapid board turnover and minor disclosure errors warrant caution.
On the evidence available, the risk–reward is unfavourable for fundamentals-driven investors: the downside is cushioned by cash, but the valuation already embeds substantial success. Key evidence to change this view would be a narrowing of losses in FY2026, positive operating cash flow from the reagent segment, and transparent disclosure of any transactions with the controller's other businesses.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Age (AR2025) | Background and education |
|---|---|---|---|---|
Dr. Zhou Xunyong (周訓勇) | Co-chairman, Executive Director; controlling shareholder | 20 Nov 2025 | 50 | Entrepreneur/researcher in enzyme-based theory for food, cosmetics, daily chemicals and tea; holds over 20 patents; author of a book on enzyme-based immune balance. BEng (Business Administration), Tianjin University (2002); Master of Laws, Fudan University (2011); DBA, Université Nice Sophia Antipolis (2016). Honorary chair, Vaccine and Immune Health Branch, Liaoning Immunology Society; committee member, national enzyme and fermentation engineering body. Director of Nasdaq-listed DT Cloud Star Acquisition Corp (from 26 Nov 2025) and Linkage Global Inc (from 13 Feb 2026), both resigned April 2026. Named a 2026 Forbes China industry pioneer innovator |
Ms. Zhang Yujing (張玉靜) | Co-chairman, Executive Director; Nomination Committee chair; holds 9% of Keyue directly | 16 Apr 2025 (chair from 29 Aug 2025; co-chair from 20 Nov 2025) | 42 | Healthcare industry experience; responsible for business operations and board management. Graduate of Hunan Women's University (2007) |
Mr. Zhang Chunguang (張春光) | Executive Director and CEO | Joined group Jul 2008; director 3 Aug 2017 | 58 | Over 10 years in PRC IVD reagents; Hubei Institute of Economics (economic English). Brother of former chairman Zhang Shuguang. Holds 3,976,000 shares (0.8%) |
Mr. Poon Lai Yin Michael (潘禮賢) | Executive Director, CFO, Compliance Officer | 3 Aug 2017 | 54 | 20+ years in audit, financial reporting and corporate finance (ex-Arthur Andersen). York University (BA), Monash (MPA), CityU HK (EMBA 2022), Tsinghua (MPA 2024); FCPA (HKICPA), CPA Australia. INED of LFG Investment (3938.HK) and Niche-Tech (8490.HK). Holds 4,000,000 shares (0.8%) |
Dr. Bu Su (卜素) | Non-executive Director | 8 Aug 2024 | 53 | 20+ years in molecular biomedicine and bioengineering; associate professor, Nanjing Forestry University (from 2014); former researcher at Amano Enzyme Inc. (Japan, 1998–2001); postdoctoral/research roles at University of Alabama at Birmingham; PhD Biochemistry, CUHK (2004) |
Dr. Chow Kwok Fai Joseph (周國輝) | INED | 16 Dec 2020 | 53 | CEO of Zhejiang Thunderbio Innovation (molecular diagnostics, microfluidics) since 2018; BSc Monash; MMedSc and PhD, HKU |
Mr. Tsui Wing Tak (徐永得) | INED; Audit Committee chair | 22 Jan 2025 | 57 | 30+ years in accounting; FCPA (HKICPA), CPA (Australia); ED of KNT Holdings (1025.HK); INED of Bingo Group (8220.HK) |
Ms. Wang Yachun (王亞純) | INED; Remuneration Committee chair | 30 Jun 2025 | 42 | Director of Jiangsu Zhengzhe Financial Management Consulting; BAcc, Hunan Agricultural University (2008); passed PRC CPA professional-stage exams (2014) |
Executive Leadership Team
| Name | Role | Joined | Age | Background |
|---|---|---|---|---|
Mr. Chau Lai Ki (周麗麒) | Financial Controller and Company Secretary | 25 Sep 2017 | 42 | Practising member HKICPA; MPA PolyU; 20+ years finance |
Mr. Fu Jianhua (傅劍華) | Deputy GM and CTO, Shenzhen Huakang | Jan 2014 | 60 | BSc Wuhan University; 20+ years in medical devices and IVD |
Board of Directors — Ms. Chow Ching Man
| Name | Role | Departure date | Context |
|---|---|---|---|
Ms. Chow Ching Man | INED | 22 Jan 2025 | Replaced by Tsui Wing Tak |
Ms. Shih Mei Ling | INED | 28 Feb 2025 | Served under three months |
Mr. He Jiaming | Executive Director | 16 Apr 2025 | Same day Zhang Yujing appointed and Keyue deal signed |
Dr. Cheng Faat Ting Gary | INED | 8 Jul 2025 | Replaced by Wang Yachun |
Mr. Zhang Shuguang | Chairman, Executive Director | 29 Aug 2025 | Founder exit; had sold controlling vehicle Crystal Grant in Jan 2025; 4,000,000 options cancelled |
Dr. Xu Ming | Non-executive Director | 30 Mar 2026 | Reason not stated in retrieved filings |
Directors' Remuneration
| Director emoluments (CNY K) | H1 2025 | H1 2026 |
|---|---|---|
Salaries, bonuses and other benefits | 1,167 | 1,281 |
Defined contribution plan contributions | 119 | 108 |
Total | 1,286 | 1,389 |
Directors' Remuneration by Attribute
| Attribute | Status |
|---|---|
Board size | 8 (after Xu Ming's resignation 30 Mar 2026); 9 at AR2025 date |
Composition | 4 executive, 1 non-executive, 3 INEDs |
Independence | 3 of 8 = 37.5% (meets GEM one-third minimum) |
Gender | 3 female directors at AR2025 date (Zhang Yujing, Bu Su, Wang Yachun) |
Chair/CEO separation | Yes — co-chairs (Zhou, Zhang Yujing); CEO Zhang Chunguang |
Audit Committee | Tsui Wing Tak (chair), Chow Kwok Fai Joseph, Wang Yachun — all INEDs; 4 meetings in FY2025 |
Remuneration Committee | Wang Yachun (chair), Chow Kwok Fai Joseph, Zhang Chunguang (ED); 5 meetings in FY2025 |
Nomination Committee | Zhang Yujing (chair, ED), Chow Kwok Fai Joseph, Tsui Wing Tak, Wang Yachun; 6 meetings in FY2025 |
Board meetings FY2025 | 20 (plus 5 Independent Board Committee meetings related to the offer) |
Major Shareholders
| Holder | Shares | % | Note |
|---|---|---|---|
Anselme Limited (Dr. Zhou Xunyong) | 259,520,000 | 50.35 | Controlling shareholder |
Poon Lai Yin Michael | 4,000,000 | 0.78 | Director |
Zhang Chunguang | 3,976,000 | 0.77 | Director |
Public float | ≈247,976,000 | ≈48.1 | Derived |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning relative to Joyzyme |
|---|---|---|
Male fertility / andrology diagnostics (PRC) | Beijing Weili New Century Science & Technology (WLJY) | Domestic computer-assisted semen analysis (CASA) systems; instrument-led competitor in andrology labs |
Male fertility / reproductive diagnostics (global) | Hamilton Thorne | Global CASA and ART laboratory equipment; premium segment |
Chemiluminescence IVD (PRC) | Shenzhen New Industries Biomedical Engineering (Snibe) | Large-scale CLIA platform vendor; potential competitor for AMH/reproductive hormone assays |
Chemiluminescence IVD (PRC) | Autobio Diagnostics | Large CLIA and microbiology IVD vendor |
Chemiluminescence / broad IVD (PRC) | Mindray Medical | China's largest medical device group; CLIA immunoassay platforms |
Broad IVD (PRC) | Maccura Biotechnology | Clinical chemistry and immunoassay reagents |
Point-of-care / rapid tests (PRC) | Guangzhou Wondfo Biotech | Rapid tests including reproductive health; strong distribution |
ART consumables (global) | Vitrolife Group | Global leader in IVF media and consumables |
ART consumables (global) | CooperSurgical | Fertility consumables, devices and genomics |
ART media (global) | FUJIFILM Irvine Scientific | IVF media and reagents |
Women's health / supplements (PRC) | By-health (湯臣倍健) | China's leading VDS brand; massive scale versus Keyue |
Women's / family nutrition (PRC/ANZ) | H&H Group (Swisse) | Premium supplements; strong cross-border e-commerce |
Competitor Detail
| Metric | Joyzyme FY2025 |
|---|---|
Revenue (CNY Mn) | 28.28 |
Revenue growth (%) | 11.5 |
Gross margin (%) | 62.8 |
Operating margin (%) | -24.5 |
R&D intensity (%) | 11.3 |
Recent Developments
Not identified in the period: * layoffs, litigation, regulatory sanctions, guidance revisions, or contract wins with named customers.



